Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Clinical Phase
NA
Total Enrollment
320 participants
Study Classification
INTERVENTIONAL
Study Start Date
2010-02-13
Study Completion Date
2010-08-14
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This is a multicenter, post market surveillance study designed to evaluate biomarkers of tobacco exposure and effect, health status measurements, and tobacco product usage patterns in subjects who are natural adopters of cigarettes and/or smokeless tobacco. Non tobacco users will serve as a non use comparison group. This study is unblinded by necessity due to the very different visual appearance of the subject's Usual Brand (UB) of tobacco product(s).
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Comparison Across Treatment Conditions to Reduce Smokeless Tobacco Use
NCT00218296
Tobacco Use Disorder
COMPLETED
PHASE2
Switching From Usual Brand Cigarettes to a Tobacco-heating Cigarette or Snus
NCT02061917
Cigarette Smoking
COMPLETED
NA
Novel Determinants and Measures of Smokeless Tobacco Use: Study 1
NCT01067586
Smokeless Tobacco Use
Tobacco Dependence
COMPLETED
Project 1, Study 2: The Combined Impact of Nicotine Replacement and Spectrum Cigarettes
NCT02301325
Cigarette Smoking
COMPLETED
NA
Smartphone Application for Smoking Cessation
NCT02134509
Smoking
COMPLETED
NA
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
A total of approximately 320 subjects will be enrolled in parallel in one of the following 6 cohorts based on tobacco usage:
* Exclusive moist snuff users (n=50)
* Exclusive Camel SNUS users (n=50)
* Dual users of Camel SNUS and cigarettes (n=50)
* Dual users of moist snuff and cigarettes (n=50)
* Exclusive cigarette smokers (n=40 males and 20 females)
* Non tobacco users (n=40 males and 20 females)
The study duration will be 5.5 weeks or less, depending upon the study procedures required for the subject's specific cohort. The study duration includes screening up to 35 days prior to clinic check in (Day 1) and a 2 day confinement period of approximately 24 hours (Day 1 and Day 2). Subjects will be discharged in the morning on Day 2.
At the Initial Screening Visit, clinical study staff will perform screening assessments. Tobacco users will be instructed to provide a sufficient supply of their UB product(s) for use during pre-clinic procedures (i.e., pre-clinic used tobacco product collections) and for use during clinic confinement.
Prior to checking in for clinic confinement, subjects will return to the clinic for a Pre-Enrollment Outpatient Visit to assess enrollment eligibility related to the safe completion of triplicate spirometry and to pick up used tobacco product collection kits and/or urine collection containers for pre-clinic collection procedures. Within 14 days prior to clinic admission, subjects will be instructed, depending on their tobacco cohort, to continue smoking and/or using Camel SNUS or moist snuff at their normal rates and to collect their used cigarette butts (1 day collection) and/or used snus pouches (7 day collection), and retain the labeled snuff containers (1 day usage). Subjects will turn in their used tobacco product collections upon clinic check in.
Subjects will report to the clinical research unit in the morning on Day 1 for baseline testing, confirmation of continued study eligibility, check in of their UB tobacco product(s), and return of their urine collection containers and used tobacco product collections. Subjects will be allowed to use their UB tobacco product(s) ad libitum; tobacco products will be stored by clinic staff and will be dispensed subsequent to subject request, as allowed during scheduled study procedures (i.e., questionnaires, spirometry, carboxyhemoglobin, 6MWT \[six-minute walk test\]). Each UB product usage will be recorded. At approximately 2200, fasting (from all food and drink except water) and tobacco abstention will begin. Subjects must agree to remain abstinent for approximately 8-10 hours and until all Day 2 fasting procedures (i.e., samples for biomarkers of tobacco effect and exposure) have been completed.
* Exclusive moist snuff users (n=50)
* Exclusive Camel SNUS users (n=50)
* Dual users of Camel SNUS and cigarettes (n=50)
* Dual users of moist snuff and cigarettes (n=50)
* Exclusive cigarette smokers (n=40 males and 20 females)
* Non tobacco users (n=40 males and 20 females)
The study duration will be 5.5 weeks or less, depending upon the study procedures required for the subject's specific cohort. The study duration includes screening up to 35 days prior to clinic check in (Day 1) and a 2 day confinement period of approximately 24 hours (Day 1 and Day 2). Subjects will be discharged in the morning on Day 2.
At the Initial Screening Visit, clinical study staff will perform screening assessments. Tobacco users will be instructed to provide a sufficient supply of their UB product(s) for use during pre-clinic procedures (i.e., pre-clinic used tobacco product collections) and for use during clinic confinement.
Prior to checking in for clinic confinement, subjects will return to the clinic for a Pre-Enrollment Outpatient Visit to assess enrollment eligibility related to the safe completion of triplicate spirometry and to pick up used tobacco product collection kits and/or urine collection containers for pre-clinic collection procedures. Within 14 days prior to clinic admission, subjects will be instructed, depending on their tobacco cohort, to continue smoking and/or using Camel SNUS or moist snuff at their normal rates and to collect their used cigarette butts (1 day collection) and/or used snus pouches (7 day collection), and retain the labeled snuff containers (1 day usage). Subjects will turn in their used tobacco product collections upon clinic check in.
Subjects will report to the clinical research unit in the morning on Day 1 for baseline testing, confirmation of continued study eligibility, check in of their UB tobacco product(s), and return of their urine collection containers and used tobacco product collections. Subjects will be allowed to use their UB tobacco product(s) ad libitum; tobacco products will be stored by clinic staff and will be dispensed subsequent to subject request, as allowed during scheduled study procedures (i.e., questionnaires, spirometry, carboxyhemoglobin, 6MWT \[six-minute walk test\]). Each UB product usage will be recorded. At approximately 2200, fasting (from all food and drink except water) and tobacco abstention will begin. Subjects must agree to remain abstinent for approximately 8-10 hours and until all Day 2 fasting procedures (i.e., samples for biomarkers of tobacco effect and exposure) have been completed.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Smoking, Tobacco
Smoking Behaviors
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
NON_RANDOMIZED
Intervention Model
PARALLEL
Primary Study Purpose
OTHER
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Moist Snuff users
Subjects for whom moist snuff is their usual brand of tobacco product.
Group Type
OTHER
Moist Snuff
Intervention Type
OTHER
Moist Snuff product
Camel Snus users
Subjects for whom Camel Snus is their usual brand of tobacco product.
Group Type
OTHER
Camel Snus
Intervention Type
OTHER
Camel Snus product
Dual users of Camel Snus and cigarette
Subjects who use both Camel Snus and cigarettes as their usual brands of tobacco products.
Group Type
OTHER
Camel Snus
Intervention Type
OTHER
Camel Snus product
Cigarettes
Intervention Type
OTHER
Cigarette product
Dual users of moist snuff and cigarettes
Subjects who use both moist snuff and cigarettes as their usual brands of tobacco products.
Group Type
OTHER
Moist Snuff
Intervention Type
OTHER
Moist Snuff product
Cigarettes
Intervention Type
OTHER
Cigarette product
Cigarette smokers
Subjects for whom cigarettes is their usual brand of tobacco product.
Group Type
OTHER
Cigarettes
Intervention Type
OTHER
Cigarette product
Non-tobacco users
Subjects who do not use tobacco products.
Group Type
OTHER
No tobacco usage
Intervention Type
OTHER
No tobacco usage
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Moist Snuff
Moist Snuff product
Intervention Type
OTHER
Camel Snus
Camel Snus product
Intervention Type
OTHER
Cigarettes
Cigarette product
Intervention Type
OTHER
No tobacco usage
No tobacco usage
Intervention Type
OTHER
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Able to comprehend and willing to sign an informed consent form.
2. Male or female subjects at least 19 years of age.
3. Able to safely perform all study procedures, as determined by the site Investigator.
4. Willing to perform all study procedures and to consume only the meals/snacks provided while confined to the clinic.
5. Agree to not use drugs of abuse over the course of the study, and test negative for drugs of abuse.
6. Test negative for breath alcohol (by breathalyzer).
7. For tobacco users: do NOT intend to quit smoking nor intend to quit using oral smokeless tobacco products (STP) leading up to study participation (defined as planning a quit attempt within a month of the Initial Screening Visit).
8. For tobacco users: willing to abstain from tobacco use for up to 10 hours during overnight confinement in the clinic.
9. Able to read, understand, and complete questionnaires in English.
10. Meet cohort specific requirements as follows:
* Moist Snuff Users: Must be exclusive moist snuff users of any brand, any style, and any flavor who self-report using on average ≥ 1 can per week for at least 6 months prior to study entry, have an expired carbon monoxide (ECO) level of 0 to 5 ppm, and have a positive urine cotinine screen. Note: Subjects with an ECO level of 6 to 10 ppm may be included upon joint review by the Sponsor and Investigator.
* Camel SNUS Users: Must be exclusive Camel SNUS users of any variety who self report using on average ≥ 1 tin per week for at least 6 months prior to study entry, have an ECO level of 0 to 5 ppm, and have a positive urine cotinine screen. Note: Subjects with an ECO level of 6 to 10 ppm may be included upon joint review by the Sponsor and Investigator.
* Dual Camel SNUS/Cigarette Users: Must be dual users of Camel SNUS and allowed commercial filtered tobacco burning cigarettes, using on average ≥ 1 tin of Camel SNUS per week and smoking ≥ 5 cigarettes daily for at least 6 months prior to study entry. The subject's ECO level must be from 5 to 100 ppm, and the urine cotinine screen must be positive.
* Dual Moist Snuff/Cigarette Users: Must be dual users of moist snuff and allowed commercial filtered tobacco burning cigarettes, using on average ≥ 1 can of snuff per week and smoking ≥ 5 cigarettes daily for at least 6 months prior to study entry. The subject's ECO level must be from 5 to 100 ppm, and the urine cotinine screen must be positive.
* Cigarette Smokers: Must be exclusive cigarette smokers (of allowed commercial filtered tobacco burning cigarettes) who self-report smoking on average ≥ 10 cigarettes daily for at least 6 months prior to study entry, have an ECO level of 10 to 100 ppm, and have a positive urine cotinine screen.
* Non Tobacco Users: Must be non tobacco users for at least 12 months prior to study entry with an ECO level of 0 to 5 ppm, and have a negative urine cotinine screen. Note: Subjects with an ECO level of 6 to 10 ppm may be included upon joint review by the Sponsor and Investigator.
2. Male or female subjects at least 19 years of age.
3. Able to safely perform all study procedures, as determined by the site Investigator.
4. Willing to perform all study procedures and to consume only the meals/snacks provided while confined to the clinic.
5. Agree to not use drugs of abuse over the course of the study, and test negative for drugs of abuse.
6. Test negative for breath alcohol (by breathalyzer).
7. For tobacco users: do NOT intend to quit smoking nor intend to quit using oral smokeless tobacco products (STP) leading up to study participation (defined as planning a quit attempt within a month of the Initial Screening Visit).
8. For tobacco users: willing to abstain from tobacco use for up to 10 hours during overnight confinement in the clinic.
9. Able to read, understand, and complete questionnaires in English.
10. Meet cohort specific requirements as follows:
* Moist Snuff Users: Must be exclusive moist snuff users of any brand, any style, and any flavor who self-report using on average ≥ 1 can per week for at least 6 months prior to study entry, have an expired carbon monoxide (ECO) level of 0 to 5 ppm, and have a positive urine cotinine screen. Note: Subjects with an ECO level of 6 to 10 ppm may be included upon joint review by the Sponsor and Investigator.
* Camel SNUS Users: Must be exclusive Camel SNUS users of any variety who self report using on average ≥ 1 tin per week for at least 6 months prior to study entry, have an ECO level of 0 to 5 ppm, and have a positive urine cotinine screen. Note: Subjects with an ECO level of 6 to 10 ppm may be included upon joint review by the Sponsor and Investigator.
* Dual Camel SNUS/Cigarette Users: Must be dual users of Camel SNUS and allowed commercial filtered tobacco burning cigarettes, using on average ≥ 1 tin of Camel SNUS per week and smoking ≥ 5 cigarettes daily for at least 6 months prior to study entry. The subject's ECO level must be from 5 to 100 ppm, and the urine cotinine screen must be positive.
* Dual Moist Snuff/Cigarette Users: Must be dual users of moist snuff and allowed commercial filtered tobacco burning cigarettes, using on average ≥ 1 can of snuff per week and smoking ≥ 5 cigarettes daily for at least 6 months prior to study entry. The subject's ECO level must be from 5 to 100 ppm, and the urine cotinine screen must be positive.
* Cigarette Smokers: Must be exclusive cigarette smokers (of allowed commercial filtered tobacco burning cigarettes) who self-report smoking on average ≥ 10 cigarettes daily for at least 6 months prior to study entry, have an ECO level of 10 to 100 ppm, and have a positive urine cotinine screen.
* Non Tobacco Users: Must be non tobacco users for at least 12 months prior to study entry with an ECO level of 0 to 5 ppm, and have a negative urine cotinine screen. Note: Subjects with an ECO level of 6 to 10 ppm may be included upon joint review by the Sponsor and Investigator.
Exclusion Criteria
1. Use of any type of non-tobacco nicotine-containing product/device (e.g., electronic cigarette) or any nicotine replacement therapy (e.g., nicotine patch, nicotine gum, nicotine spray, nicotine inhaler or nicotine lozenge) within 6 months prior to study entry or during the study.
2. Unable to safely perform the study procedures, as determined by the site Investigator. In general, subjects with any of the conditions listed below will be excluded unless individually approved by the Medical Monitor.
1. Uncontrolled hypertension (blood pressure \> 170/110 mmHg at the Initial Screening Visit).
2. Unstable coronary artery disease (Class III-IV angina).
3. Decompensated (Class III-IV) congestive heart failure.
4. Morbid obesity (body mass index \[BMI\] ≥ 40 kg/m2).
5. Uncontrolled diabetes (HgbA1c \> 9.0).
6. Pulmonary disease requiring oxygen therapy or preventing 6 minutes of steady ambulation or preventing completion of triplicate spirometry.
7. Reduced mobility that impairs satisfactory completion of the 6MWT (six minute walk test), such as:
i. Clinically significant arthritis of the knee or hip.
ii. Claudication with walking 6 minutes or less.
iii. Clinically significant ambulation impairment as sequelae of cerebrovascular accident (CVA), sciatica, peripheral nervous disease, or myopathy.
iv. Imbalance or other gait disorder requiring assistance of a cane or walker to ambulate.
3. Have a resting heart rate (after being seated for at least 5 minutes) of \> 120 beats per minute (bpm).
4. Had a myocardial infarction within the month prior to the Initial Screening Visit through enrollment into the study.
5. Have self reported or clinical indications of psychiatric disorders deemed clinically significant by the site Investigator.
6. Unwilling to perform the study procedures.
7. For females: intend to get pregnant during study period, or are currently pregnant or breast feeding.
8. For cigarette- and dual-users:
1. use of any charcoal-filtered cigarette (i.e., brands such as Lark, Kent, etc., with the word "charcoal" on the package),
2. use of any crush-capsule cigarette (such as Camel Crush or Pall Mall Crush), or
3. use of any non tobacco burning cigarette, including tobacco heating cigarettes (such as Eclipse, Accord, etc.) or electronic cigarettes (e-cigarettes such as Smoking Anywhere, Gamucci, NJOY, etc.).
9. For tobacco users: express an interest in quitting smoking or using oral smokeless tobacco (defined as planning a quit attempt within a month of the Initial Screening Visit).
10. Have participated in a clinical study and/or received an investigational product within 30 days of the Initial Screening Visit.
11. Meet cohort specific exclusions as follows:
* Moist Snuff Users: For 6 months prior to the study through Day 1, the use of any other tobacco- or nicotine-containing product or device other than moist snuff (of any brand, style, and flavor), including tobacco-burning cigarettes, tobacco-heating cigarettes, e cigarettes, cigars, pipes, chewing tobacco, dry snuff, snus, etc.; a negative urine cotinine screen; or an ECO greater than 5 ppm (ECO of 6 to 10 ppm may not exclude based upon joint review by the Sponsor and Investigator).
* Camel SNUS Users: For 6 months prior to the study through Day 1, the use of any tobacco- or nicotine-containing product or device other than Camel SNUS (of any variety), including tobacco-burning cigarettes, tobacco-heating cigarettes, e cigarettes, cigars, pipes, chewing tobacco, dry snuff, moist snuff, other snus brands, etc.; a negative urine cotinine screen; or an ECO greater than 5 ppm (ECO of 6 to 10 ppm may not exclude based upon joint review by the Sponsor and Investigator).
* Dual Camel SNUS/Cigarette Users: For 6 months prior to the study through Day 1, the use of any tobacco- or nicotine-containing product or device other than Camel SNUS (of any variety) and tobacco burning cigarettes (allowed commercial filtered cigarettes), including tobacco-heating cigarettes, e cigarettes, cigars, pipes, chewing tobacco, dry snuff, moist snuff, other snus brands, etc.; a negative urine cotinine screen; or an ECO less than 5 or greater than 100 ppm.
* Dual Moist Snuff/Cigarette Users: For 6 months prior to the study through Day 1, the use of any tobacco- or nicotine-containing product or device other than moist snuff (of any brand, style, and flavor) and tobacco burning cigarettes (allowed commercial filtered cigarettes), including tobacco-heating cigarettes, e cigarettes, cigars, pipes, chewing tobacco, dry snuff, snus, etc.; a negative urine cotinine screen; or an ECO less than 5 or greater than 100 ppm.
* Cigarette Smokers: For 6 months prior to the study through Day 1, the use of any tobacco- or nicotine-containing product or device other than tobacco burning cigarettes (allowed commercial filtered cigarettes), including tobacco-heating cigarettes, e cigarettes, cigars, pipes, chewing tobacco, dry snuff, moist snuff, snus, etc.; a negative urine cotinine screen; or an ECO less than 10 or greater than 100 ppm.
* Non Tobacco Users: In their lifetime, the use of more than 20 packs of cigarettes; the use of more than 10 cans, tins, or packs of any smokeless tobacco (chewing tobacco, dry snuff, moist snuff, snus); the use of more than 20 cigars; the use of more than 20 pipes of tobacco; the use of any nicotine replacement therapy, the use of any e cigarette, or use of any combination thereof; a positive urine cotinine screen; or an ECO greater than 5 ppm (ECO of 6 to 10 ppm may not exclude based upon joint review by the Sponsor and Investigator).
2. Unable to safely perform the study procedures, as determined by the site Investigator. In general, subjects with any of the conditions listed below will be excluded unless individually approved by the Medical Monitor.
1. Uncontrolled hypertension (blood pressure \> 170/110 mmHg at the Initial Screening Visit).
2. Unstable coronary artery disease (Class III-IV angina).
3. Decompensated (Class III-IV) congestive heart failure.
4. Morbid obesity (body mass index \[BMI\] ≥ 40 kg/m2).
5. Uncontrolled diabetes (HgbA1c \> 9.0).
6. Pulmonary disease requiring oxygen therapy or preventing 6 minutes of steady ambulation or preventing completion of triplicate spirometry.
7. Reduced mobility that impairs satisfactory completion of the 6MWT (six minute walk test), such as:
i. Clinically significant arthritis of the knee or hip.
ii. Claudication with walking 6 minutes or less.
iii. Clinically significant ambulation impairment as sequelae of cerebrovascular accident (CVA), sciatica, peripheral nervous disease, or myopathy.
iv. Imbalance or other gait disorder requiring assistance of a cane or walker to ambulate.
3. Have a resting heart rate (after being seated for at least 5 minutes) of \> 120 beats per minute (bpm).
4. Had a myocardial infarction within the month prior to the Initial Screening Visit through enrollment into the study.
5. Have self reported or clinical indications of psychiatric disorders deemed clinically significant by the site Investigator.
6. Unwilling to perform the study procedures.
7. For females: intend to get pregnant during study period, or are currently pregnant or breast feeding.
8. For cigarette- and dual-users:
1. use of any charcoal-filtered cigarette (i.e., brands such as Lark, Kent, etc., with the word "charcoal" on the package),
2. use of any crush-capsule cigarette (such as Camel Crush or Pall Mall Crush), or
3. use of any non tobacco burning cigarette, including tobacco heating cigarettes (such as Eclipse, Accord, etc.) or electronic cigarettes (e-cigarettes such as Smoking Anywhere, Gamucci, NJOY, etc.).
9. For tobacco users: express an interest in quitting smoking or using oral smokeless tobacco (defined as planning a quit attempt within a month of the Initial Screening Visit).
10. Have participated in a clinical study and/or received an investigational product within 30 days of the Initial Screening Visit.
11. Meet cohort specific exclusions as follows:
* Moist Snuff Users: For 6 months prior to the study through Day 1, the use of any other tobacco- or nicotine-containing product or device other than moist snuff (of any brand, style, and flavor), including tobacco-burning cigarettes, tobacco-heating cigarettes, e cigarettes, cigars, pipes, chewing tobacco, dry snuff, snus, etc.; a negative urine cotinine screen; or an ECO greater than 5 ppm (ECO of 6 to 10 ppm may not exclude based upon joint review by the Sponsor and Investigator).
* Camel SNUS Users: For 6 months prior to the study through Day 1, the use of any tobacco- or nicotine-containing product or device other than Camel SNUS (of any variety), including tobacco-burning cigarettes, tobacco-heating cigarettes, e cigarettes, cigars, pipes, chewing tobacco, dry snuff, moist snuff, other snus brands, etc.; a negative urine cotinine screen; or an ECO greater than 5 ppm (ECO of 6 to 10 ppm may not exclude based upon joint review by the Sponsor and Investigator).
* Dual Camel SNUS/Cigarette Users: For 6 months prior to the study through Day 1, the use of any tobacco- or nicotine-containing product or device other than Camel SNUS (of any variety) and tobacco burning cigarettes (allowed commercial filtered cigarettes), including tobacco-heating cigarettes, e cigarettes, cigars, pipes, chewing tobacco, dry snuff, moist snuff, other snus brands, etc.; a negative urine cotinine screen; or an ECO less than 5 or greater than 100 ppm.
* Dual Moist Snuff/Cigarette Users: For 6 months prior to the study through Day 1, the use of any tobacco- or nicotine-containing product or device other than moist snuff (of any brand, style, and flavor) and tobacco burning cigarettes (allowed commercial filtered cigarettes), including tobacco-heating cigarettes, e cigarettes, cigars, pipes, chewing tobacco, dry snuff, snus, etc.; a negative urine cotinine screen; or an ECO less than 5 or greater than 100 ppm.
* Cigarette Smokers: For 6 months prior to the study through Day 1, the use of any tobacco- or nicotine-containing product or device other than tobacco burning cigarettes (allowed commercial filtered cigarettes), including tobacco-heating cigarettes, e cigarettes, cigars, pipes, chewing tobacco, dry snuff, moist snuff, snus, etc.; a negative urine cotinine screen; or an ECO less than 10 or greater than 100 ppm.
* Non Tobacco Users: In their lifetime, the use of more than 20 packs of cigarettes; the use of more than 10 cans, tins, or packs of any smokeless tobacco (chewing tobacco, dry snuff, moist snuff, snus); the use of more than 20 cigars; the use of more than 20 pipes of tobacco; the use of any nicotine replacement therapy, the use of any e cigarette, or use of any combination thereof; a positive urine cotinine screen; or an ECO greater than 5 ppm (ECO of 6 to 10 ppm may not exclude based upon joint review by the Sponsor and Investigator).
Minimum Eligible Age
19 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
RAI Services Company
INDUSTRY
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Bobbette Jones, DrPH
Role: STUDY_DIRECTOR
RAIS
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Avail Clinical Research
DeLand, Florida, United States
Site Status
Comprehensive Clinical Development, Inc.
Miramar, Florida, United States
Site Status
Clinical Research Atlanta
Stockbridge, Georgia, United States
Site Status
Central Kentucky Research Associates (CKRA)
Lexington, Kentucky, United States
Site Status
MetaClin Research, Inc.
Austin, Texas, United States
Site Status
Community Clinical Research
Austin, Texas, United States
Site Status
Countries
Review the countries where the study has at least one active or historical site.
United States
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CSD0904
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Influence of Authorized Smokeless Tobacco Product Modified Risk Claims I: Consumer Product Demand
NCT07102082
RECRUITING
NA
Effects of FDA Authorized Smokeless Tobacco Claims Among US Adults Who Smoke Cigarettes
NCT06927700
COMPLETED
NA
Mobile Sensing of Smoking Behavior
NCT02116283
COMPLETED
NA
Assessing the Use of Nicotine Gum to Decrease Betel Nut Chewing in Saipan
NCT05758298
WITHDRAWN
EARLY_PHASE1
Promoting Home Smoking Restrictions: Biomarker Feedback to Smoking and Non-Smoking Adults
NCT01497158
COMPLETED
NA
Effectiveness of Using Tobacco Free Snuff in Reducing Negative Effects of Smokeless Tobacco Use
NCT00218270
COMPLETED
PHASE2
BAT3221032: A Study to Evaluate the Effects of Switching From Cigarette Smoking to Using One of Five Variants of a Heated Tobacco Product on Biomarkers of Exposure and Biomarkers of Potential Harm in Healthy Subjects
NCT05142436
COMPLETED
NA
Testing the Efficacy of A Scalable, Telephone-Delivered, Guided Imagery Tobacco Cessation Intervention
NCT05277831
COMPLETED
NA
Health Effects of SLT, Cigarette Smoking, and New Tobacco Products
NCT00469079
COMPLETED
PHASE2
Identifying Optimal Smoking Cessation Intervention Components (Cessation)
NCT01116986
COMPLETED
PHASE4
Novel Determinants and Measures of Smokeless Tobacco Use: Study 2
NCT01067599
COMPLETED
NA
An Experimental Evaluation of Menthol-Flavored Tobacco Accessories
NCT07092501
RECRUITING
NA
The Impact of Cigarillo Warnings on Purchasing
NCT05434013
COMPLETED
NA
A Text-based Reduction Intervention for Smokeless Tobacco Cessation
NCT04315506
COMPLETED
NA
Re-Connect Application for Smoking Cessation
NCT05224154
RECRUITING
NA
Project 1, Study 1: Investigating the Impact of Nicotine Using Spectrum Cigarettes
NCT01681875
COMPLETED
NA
Nicotine Lozenge to Reduce Smokeless Tobacco Use
NCT00218283
COMPLETED
PHASE2
Informing Tobacco Treatment Guidelines for African American Non-Daily Smokers
NCT02244918
COMPLETED
PHASE4
Smokers' Health Project: Self-Determination and Maintaining Tobacco Abstinence
NCT00178685
COMPLETED
PHASE4
Free Samples for Health
NCT05627596
ENROLLING_BY_INVITATION
PHASE2
Project 2: Strategies for Reducing Nicotine Content in Cigarettes
NCT02139930
COMPLETED
NA
Development of Biomarkers of Effect From Chronic Tobacco Usage
NCT01923402
COMPLETED
A Test of Short and Long Term Naturalistic Outcomes of Smokers Who Sample Smokeless Tobacco
NCT01509586
COMPLETED
NA
Cooling Agent Pilot Among Adult Menthol Smokers
NCT06477601
COMPLETED
NA
Responses of Adults Smoking Nondaily and Daily in the Experimental Tobacco Marketplace
NCT06988371
COMPLETED
NA